HC Wainwright Issues Positive Forecast for OVID Earnings

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Ovid to ($0.08) from ($0.09) and maintained a Buy rating with a $4.00 price target, projecting FY2026 EPS of ($0.34) versus a consensus full-year loss of ($0.40).
• Ovid beat expectations in its most recent quarter with $0.06 EPS (consensus -$0.10) and $0.72M revenue (consensus $0.06M), but still reports negative ROE and a -240% net margin while the stock trades at $2.75 against an average analyst target of $4.63.

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Ovid Therapeutics in a research note issued on Thursday, April 9th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.09). HC Wainwright has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics' FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.34) EPS.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last posted its quarterly earnings data on Wednesday, March 18th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.16. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%.The business had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.06 million.

Several other equities analysts also recently commented on OVID. Lifesci Capital began coverage on Ovid Therapeutics in a research note on Monday, December 22nd. They issued an "outperform" rating and a $4.00 price objective on the stock. Wall Street Zen upgraded Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, March 21st. Wedbush boosted their target price on shares of Ovid Therapeutics from $5.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, March 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Ovid Therapeutics in a research report on Thursday, January 22nd. Finally, BTIG Research restated a "buy" rating and set a $4.00 target price on shares of Ovid Therapeutics in a research report on Thursday, March 26th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $4.63.

Ovid Therapeutics Price Performance

Ovid Therapeutics stock opened at $2.75 on Monday. Ovid Therapeutics has a 12 month low of $0.25 and a 12 month high of $3.11. The company has a current ratio of 8.97, a quick ratio of 8.97 and a debt-to-equity ratio of 0.09. The business's 50 day simple moving average is $1.94 and its 200 day simple moving average is $1.70. The company has a market cap of $362.67 million, a price-to-earnings ratio of -8.87 and a beta of -0.03.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Benin Management CORP bought a new position in shares of Ovid Therapeutics in the fourth quarter worth $31,000. Private Advisor Group LLC bought a new position in shares of Ovid Therapeutics in the third quarter worth $33,000. Apollon Wealth Management LLC bought a new position in shares of Ovid Therapeutics in the third quarter worth $36,000. Total Clarity Wealth Management Inc. bought a new position in shares of Ovid Therapeutics in the fourth quarter worth $47,000. Finally, LPL Financial LLC increased its holdings in shares of Ovid Therapeutics by 150.0% in the fourth quarter. LPL Financial LLC now owns 30,000 shares of the company's stock worth $49,000 after purchasing an additional 18,000 shares during the period. Institutional investors own 72.24% of the company's stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company's lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.